NASDAQ:NTRA Natera (NTRA) Stock Price, News & Analysis $350.78 +8.99 (+2.63%) Closing price 09/15/2026 04:00 PM EasternExtended Trading$355.62 +4.84 (+1.38%) As of 09/15/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Natera Stock (NASDAQ:NTRA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Natera alerts:Sign Up Key Stats Today's Range$338.82▼$351.7850-Day Range$252.22▼$350.7852-Week Range$157.43▼$351.78Volume1.77 million shsAverage Volume1.07 million shsMarket Capitalization$50.56 billionP/E RatioN/ADividend YieldN/APrice Target$330.83Consensus RatingModerate Buy Company Overview Natera, Inc. is a diagnostics company that develops and commercializes molecular testing services based on cell-free DNA and other genomic technologies. The company focuses on reproductive health, oncology and organ health, providing tests intended to support screening, diagnosis, treatment planning and disease monitoring. Its reproductive health portfolio includes Panorama, a noninvasive prenatal test that screens for certain chromosomal conditions, and Horizon, a carrier screening test. In oncology, Natera offers Signatera, a personalized circulating tumor DNA test used to help monitor minimal residual disease and assess recurrence risk. Its organ health business includes Prospera, a molecular transplant assessment designed to help evaluate organ rejection, particularly in kidney and heart transplant recipients. Founded in 2004 and headquartered in Austin, Texas, Natera serves healthcare providers, laboratories, health systems and patients in the United States and select international markets. The company is led by Chief Executive Officer Steve Chapman.AI Generated. May Contain Errors. Read More Natera Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreNTRA MarketRank™: Natera scored higher than 42% of companies evaluated by MarketBeat, and ranked 682nd out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingNatera has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 2 strong buy ratings, 16 buy ratings, 4 hold ratings, and 1 sell rating.Downside RiskNatera has a consensus price target of $330.83, representing about 5.7% downside from its current price of $350.78.Amount of Analyst CoverageNatera has been the subject of 18 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Natera's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Natera are expected to grow in the coming year, from ($1.02) to $0.01 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Natera is -257.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Natera is -257.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNatera has a P/B Ratio of 28.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Natera's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.03% of the float of Natera has been sold short.Short Interest Ratio / Days to CoverNatera has a short interest ratio ("days to cover") of 4.37.Change versus previous monthShort interest in Natera has recently increased by 28.38%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNatera does not currently pay a dividend.Dividend GrowthNatera does not have a long track record of dividend growth. News and Social Media4.5 / 5News Sentiment1.14 News SentimentNatera has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Natera this week, compared to 11 articles on an average week.Search Interest18 people have searched for NTRA on MarketBeat in the last 30 days. This is an increase of 6% compared to the previous 30 days.MarketBeat Follows20 people have added Natera to their MarketBeat watchlist in the last 30 days. This is an increase of 43% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Natera insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $19,944,069.00 in company stock.Percentage Held by Insiders5.05% of the stock of Natera is held by insiders.Percentage Held by Institutions99.90% of the stock of Natera is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Natera's insider trading history. Receive NTRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NTRA Stock News HeadlinesNatera, Inc. (NASDAQ:NTRA) Given Average Rating of "Moderate Buy" by BrokeragesSeptember 15 at 2:28 AM | americanbankingnews.comThis Surprising Stock Has Been Stanley Druckenmiller's No. 1 Position for 8 Straight Quarters.September 14 at 9:30 AM | fool.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery. | Behind the Markets (Ad)Bernstein Remains a Buy on Natera (NTRA)September 11, 2026 | theglobeandmail.comNatera (NASDAQ:NTRA) Research Coverage Started at Rothschild & Co RedburnSeptember 11, 2026 | americanbankingnews.comNatera (NASDAQ:NTRA) CEO Sells $545,041.02 in StockSeptember 4, 2026 | insidertrades.comJohn Fesko Sells 6,517 Shares of Natera (NASDAQ:NTRA) StockAugust 29, 2026 | insidertrades.com2 Biotech Stocks Shaping Up for Major Breakouts (NTRA)Moderna's mRNA cancer vaccine breakthrough with Merck fueled a biotech rally, with the IBB near highs. Eli Lilly and Natera both show strong uptrends and possible breakouts.August 22, 2026 | marketbeat.comSee More Headlines NTRA Stock Analysis - Frequently Asked Questions How have NTRA shares performed this year? Natera's stock was trading at $229.09 on January 1st, 2026. Since then, NTRA shares have increased by 53.1% and is now trading at $350.78. How were Natera's earnings last quarter? Natera, Inc. (NASDAQ:NTRA) released its earnings results on Thursday, August, 6th. The medical research company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.02. Natera's quarterly revenue was up 37.7% compared to the same quarter last year. Read the conference call transcript. When did Natera IPO? Natera (NTRA) raised $175 million in an IPO on Thursday, July 2nd 2015. The company issued 10,000,000 shares at $17.00-$18.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers. Who are Natera's major shareholders? Top institutional shareholders of Natera include BlackRock Inc. (7.62%), Wellington Management Group LLP (2.80%), UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (0.58%) and Bank of America Corp DE (0.51%). Insiders that own company stock include Roelof Botha, Matthew Rabinowitz, Daniel Rabinowitz, John Fesko, Solomon Moshkevich, Steven Leonard Chapman, Jonathan Sheena, Michael Burkes Brophy, James Healy, Roy D Baynes, Gail Boxer Marcus, Herm Rosenman and Rowan E Chapman. View institutional ownership trends. How do I buy shares of Natera? Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Natera own? Based on aggregate information from My MarketBeat watchlists, some other companies that Natera investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings8/06/2026Today9/15/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 NTRA's financial health is in the Green zone, according to TradeSmith. NTRA has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NTRA CIK1604821 Webwww.natera.com Phone(650) 249-9090FaxN/AEmployees6,140Year Founded2004Price Target and Rating Average Price Target for Natera$330.83 High Price Target$435.00 Low Price Target$172.00 Potential Upside/Downside-5.7%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage23 Analysts Profitability EPS (Trailing Twelve Months)($1.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$208.16 million Net Margins-7.11% Pretax Margin-9.33% Return on Equity-11.38% Return on Assets-7.87% Debt Debt-to-Equity RatioN/A Current Ratio3.00 Quick Ratio2.85 Sales & Book Value Annual Sales$2.71 billion Price / Sales18.68 Cash FlowN/A Price / Cash FlowN/A Book Value$12.38 per share Price / Book28.33Miscellaneous Outstanding Shares144,144,000Free Float136,865,000Market Cap$50.56 billion OptionableOptionable Beta1.54 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:NTRA) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our PartnersJon Najarian's #1 Energy Trade for 2026Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2...Banyan Hill Publishing | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...SmartAsset | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Natera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Natera With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
